MedTrace Logo

CPX-351 Real-World Effectiveness and Safety Study

NCT05169307 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 147

Last updated 2022-07-12

No results posted yet for this study

Summary

CPX-351 Real World Effectiveness and Safety Study (CREST UK) is a real-world evidence study designed to collect data on the potential benefits and/or risks of Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine clinical practice in the United Kingdom (UK).

Conditions

Interventions

DRUG

CPX-351

This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-14
Primary Completion
2022-06-15
Completion
2022-06-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169307 on ClinicalTrials.gov